Implications of Mobile Applications for Breast Surgery: A Systematic Review.

Clin Breast CancerAug 28, 2026 (epub)
Clinical ResearchGeneral SurgeryOncology (Medical)

Kwaku Duah-Asante, Thiviya Sivakanthan, Ife Oledajo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated mobile applications designed to assist patients undergoing breast surgery across various stages of care. Analyzing 20 studies, the review found that remote monitoring apps significantly reduced in-person visits without increasing complications, highlighting their effectiveness in patient management during recovery.

Key findings

  • Remote monitoring apps reduced in-person visits without increasing complications.
  • Education apps consistently reduced anxiety and improved patient satisfaction.
  • Decision-support apps reduced uncertainty and improved body image in one study.
  • Symptom-management apps showed inconsistent results, best with additional human contact.

Why it matters

Understanding the effectiveness of mobile applications in breast surgery can help clinicians better support patients throughout their surgical journey, potentially improving outcomes and patient satisfaction.

Source

PubMed · PMID 42759484

Published in Clin Breast Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.